This study was undertaken to evaluate the diagnostic performance of a novel plasma phosphorylated tau (p‐tau) 217/amyloid beta (Aβ) 42 ratio test for Alzheimer's disease (AD). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.